Tau reduction: A possible new therapeutic target for Dravet Syndrome patients
A recent study published in the Annals of Neurology by Dr. Lennart Mucke’s team at the Gladstone Institute of Neurological Disease in the University of California at San Francisco demonstrates that genetic ablation of tau in a mouse model of Dravet syndrome reverses most of the symptoms.